Literature DB >> 10225969

New protective antigen of group A streptococci.

J B Dale1, E Y Chiang, S Liu, H S Courtney, D L Hasty.   

Abstract

It is widely believed that the surface M protein of group A streptococci is the predominant surface protein of these organisms containing opsonic epitopes. In the present study, we identified a new surface protein, distinct from M protein, that evokes protective antibodies. A type 18 M-negative mutant was found to be both resistant to phagocytosis in human blood and virulent in mice. The wild-type strain, but not the M-negative mutant, was opsonized by antisera against purified recombinant M18 protein or a synthetic peptide copying the NH2-terminus of M18. However, antisera raised against a crude pepsin extract of the M-negative mutant opsonized both strains, indicating the presence of a protective antigen in addition to type 18 M protein. This antiserum was used to identify and purify a 24-kDa protein fragment (Spa, streptococcal protective antigen) that evoked antibodies that opsonized the M18 parent and the M-negative mutant. The results of passive mouse protection tests confirmed the presence of protective epitopes within Spa. The deduced amino acid sequence of a 636-bp 5' fragment of the spa18 gene showed no homology with sequences in GenBank. These studies reveal the presence of a new protective antigen of certain strains of group A streptococci that may prove to be an important component of vaccines to prevent streptococcal infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225969      PMCID: PMC408353          DOI: 10.1172/JCI5118

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis.

Authors:  D R Johnson; D L Stevens; E L Kaplan
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

2.  Cross-protection among serotypes of group A streptococci.

Authors:  S Bergner-Rabinowitz; I Ofek; M D Moody
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

3.  Recombinant tetravalent group A streptococcal M protein vaccine.

Authors:  J B Dale; E Y Chiang; J W Lederer
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

4.  Demonstration of protection in mice from a lethal challenge of three M serotypes of Streptococcus pyogenes using an M-negative vaccine.

Authors:  J D Chappell; J G Stuart
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

5.  Introduction of the emm6 gene into an emm-deleted strain of Streptococcus pyogenes restores its ability to resist phagocytosis.

Authors:  J Perez-Casal; M G Caparon; J R Scott
Journal:  Res Microbiol       Date:  1992 Jul-Aug       Impact factor: 3.992

6.  Identification of four new prokaryotic bacterioferritins, from Helicobacter pylori, Anabaena variabilis, Bacillus subtilis and Treponema pallidum, by analysis of gene sequences.

Authors:  D J Evans; D G Evans; H C Lampert; H Nakano
Journal:  Gene       Date:  1995-02-03       Impact factor: 3.688

7.  Multiple, heart-cross-reactive epitopes of streptococcal M proteins.

Authors:  J B Dale; E H Beachey
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

8.  ANTIGENIC PROPERTIES OF THE TYPE-SPECIFIC SUBSTANCE DERIVED FROM GROUP A HEMOLYTIC STREPTOCOCCI.

Authors:  G K Hirst; R C Lancefield
Journal:  J Exp Med       Date:  1939-02-28       Impact factor: 14.307

9.  Cross-reactions among Group A streptococci. I. Precipitin and bactericidal cross-reactions among types 33, 41, 43, 52, and Ross.

Authors:  G G Wiley; P N Bruno
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

10.  An immunological relationship between the group. A streptococcus and mammalian muscle.

Authors:  J B Zabriskie; E H Freimer
Journal:  J Exp Med       Date:  1966-10-01       Impact factor: 14.307

View more
  26 in total

1.  Immunogenicity of a 26-valent group A streptococcal vaccine.

Authors:  Mary C Hu; Michael A Walls; Steven D Stroop; Mark A Reddish; Bernard Beall; James B Dale
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

2.  Reduced IFN-gamma responses associated with HLA-DR15 presentation of streptococcal cell wall proteins to dermal Th-1 cells in psoriasis.

Authors:  Barbara S Baker; Jean-Marc Ovigne; Vincent A Fischetti; Anne Powles; Lionel Fry
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

3.  Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Authors:  Manisha Pandey; Michael R Batzloff; Michael F Good
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

4.  Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci.

Authors:  E A Ahmed; T A Penfound; S C Brewer; P A Tennant; E Y Chiang; J B Dale
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-10-29       Impact factor: 3.267

5.  Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice.

Authors:  S Kawabata; E Kunitomo; Y Terao; I Nakagawa; K Kikuchi; K Totsuka ; S Hamada
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 6.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

7.  Multilocus analysis of extracellular putative virulence proteins made by group A Streptococcus: population genetics, human serologic response, and gene transcription.

Authors:  S D Reid; N M Green; J K Buss; B Lei; J M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

8.  Invasive group a streptococcal infections, Israel.

Authors:  Allon E Moses; Sara Goldberg; Zinaida Korenman; Miriam Ravins; Emanuel Hanski; Mervyn Shapiro
Journal:  Emerg Infect Dis       Date:  2002-04       Impact factor: 6.883

9.  Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci.

Authors:  Harry S Courtney; David L Hasty; James B Dale
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Group A streptococcus expresses a trio of surface proteins containing protective epitopes.

Authors:  Shannon E Niedermeyer; Thomas A Penfound; Claudia Hohn; Yi Li; Ramin Homayouni; Jingnan Zhao; James B Dale
Journal:  Clin Vaccine Immunol       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.